76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
P Pharma Mar SA
P
Closed
78.7 -0.94
Overview
Share price change
24h
Min
78.5
Max
79.55
Income | -13M -3.9M |
|---|---|
Sales | -9.5M 39M |
P/E Sector Avg | 70 50.291 |
EPS | -0.22 |
Dividend yield | 0.93 |
Profit margin | -10.047 |
Employees | 500 |
EBITDA | -16M -1.1M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +35.24% upside |
Dividend yield Sector Avg | 0.93% 2.40% |
|---|---|
Next Earnings | 29 Jul 2025 |
Market Cap | 23M 1.4B |
|---|---|
Previous open | 79.64 |
Previous close | 78.7 |
Technical Score
By Trading Central
Confidence
Bearish Evidence
Pharma Mar SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pharma Mar SA Forecast
Price Target
By TipRanks
35.24% upside
12 Months Forecast
Average 109.004 EUR 35.24%
High 110 EUR
Low 108 EUR
Based on 2 Wall Street analysts offering 12 month price targets forPharma Mar SA - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
